View source for 18297417. GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF simplified abstract (WISCONSIN ALUMNI RESEARCH FOUNDATION)

=GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF=


==Organization Name==

[[:Category:WISCONSIN ALUMNI RESEARCH FOUNDATION|WISCONSIN ALUMNI RESEARCH FOUNDATION]]


[[Category:WISCONSIN ALUMNI RESEARCH FOUNDATION]]

==Inventor(s)==

[[:Category:James Thomson of Madison WI (US)|James Thomson of Madison WI (US)]][[Category:James Thomson of Madison WI (US)]]

[[:Category:Jue Zhang of Madison WI (US)|Jue Zhang of Madison WI (US)]][[Category:Jue Zhang of Madison WI (US)]]

[[:Category:John Maufort of Madison WI (US)|John Maufort of Madison WI (US)]][[Category:John Maufort of Madison WI (US)]]

==GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18297417 titled 'GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF

==Simplified Explanation==
This patent application describes allogeneic human endothelial cell-seeded polymeric vascular grafts that can replace or bypass natural blood vessels, with improved long-term patency rates and reduced leukocyte adhesion compared to grafts with venous endothelial cells.

* These vascular grafts are seeded with human endothelial cells, enhancing their performance.
* The grafts exhibit increased long-term patency rates, ensuring better functionality over time.
* Reduced leukocyte adhesion on the grafts helps prevent complications and improve overall effectiveness.
* Methods for generating these human endothelial cell-seeded vascular grafts are detailed in the application.
* The technology has therapeutic uses in replacing or bypassing natural blood vessels.

==Potential Applications==
The technology can be used in various medical procedures where vascular grafts are required, such as in cardiovascular surgeries, organ transplants, and vascular reconstructions.

==Problems Solved==
This technology addresses issues related to the patency and performance of vascular grafts, as well as reducing the risk of complications due to leukocyte adhesion.

==Benefits==
The benefits of this technology include improved long-term functionality of vascular grafts, reduced likelihood of complications, and enhanced overall success rates in medical procedures involving blood vessel replacement or bypass.

==Commercial Applications==
* Cardiovascular surgery
* Organ transplants
* Vascular reconstructions

==Questions about Allogeneic Human Endothelial Cell-Seeded Vascular Grafts==
===How do these vascular grafts compare to traditional grafts in terms of long-term patency rates?===
The allogeneic human endothelial cell-seeded vascular grafts exhibit increased long-term patency rates compared to traditional grafts, ensuring better functionality over time.

===What are the potential therapeutic uses of these human endothelial cell-seeded vascular grafts?===
These grafts can be used in various medical procedures to replace or bypass natural blood vessels, offering improved performance and reduced risk of complications.


==Original Abstract Submitted==

Provided herein are allogeneic human endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.



[[Category:A61L27/50]]
[[Category:A61L27/38]]
[[Category:C12N5/071]]
[[Category:CPC_A61L27/507]]